Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 319 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
Holders of 5% or more of TERN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Terns Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 6.80%5.74M shares | – | Oct 24, 20243 filings | Feb 5, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
78 Schedule 13D and 13G filings on Terns Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 20264:21 PM ET | Morgan Stanley | 13G/A | 0.00%0 shares | −5.60 ppfrom 5.60%Below 5% | May 31, 2026 | SEC |
| May 13, 20269:19 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 1.84%2.12M shares | −3.26 ppfrom 5.10%Below 5% | Mar 31, 2026 | SEC |
| May 12, 202611:11 AM ET | Morgan Stanleyand 1 other | 13G/A | 5.60%6.43M shares | −2.50 ppfrom 8.10% | Mar 31, 2026 | SEC |
| Mar 27, 20261:32 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.21 ppfrom 5.21%Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20264:29 PM ET | Commodore Capital LPand 3 others | 13G/A | 1.40%1.48M shares | −5.10 ppfrom 6.50%Below 5% | Dec 31, 2025 | SEC |
| Feb 13, 20266:11 PM ET | Vivo Opportunity Fund Holdings, L.P.and 6 others | 13G/A | 2.50%2.70M shares | –Below 5% | Jan 31, 2025 | SEC |
| Feb 13, 20268:52 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 2.97%3.15M shares | −5.61 ppfrom 8.58%Below 5% | Dec 31, 2025 | SEC |
| Feb 12, 20265:01 PM ET | Soleus Capital Master Fund, L.P.and 5 others | 13G/A | 0.20%212.7K shares | −9.40 ppfrom 9.60%Below 5% | Dec 31, 2025 | SEC |
| Feb 12, 20269:14 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 5.10%5.55M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 20254:51 PM ET | Commodore Capital LPand 3 others | 13G/A | 6.50%5.70M shares | +1.20 ppfrom 5.30% | Sep 30, 2025 | SEC |
| Nov 5, 20254:13 PM ET | OrbiMed Advisors LLCand 4 others | 13D/A | 4.80%4.24M shares | –Below 5% | Nov 3, 2025 | SEC |
| Oct 31, 202511:31 AM ET | Vanguard Group Inc | 13G | 5.21%4.56M shares | New | Sep 30, 2025 | SEC |
| Sep 16, 20256:00 PM ET | Commodore Capital LPand 3 others | 13G | 5.30%4.65M shares | New | Sep 9, 2025 | SEC |
| Aug 14, 20258:51 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 8.58%7.50M shares | +2.19 ppfrom 6.39% | Jun 30, 2025 | SEC |
| May 15, 20254:31 PM ET | Schonfeld Strategic Advisors LLC | 13G/A | 4.93%4.31M shares | −1.23 ppfrom 6.16%Below 5% | Mar 31, 2025 | SEC |
| May 15, 20258:47 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 6.39%5.58M shares | – | Mar 31, 2025 | SEC |
| May 7, 202511:29 AM ET | Morgan Stanleyand 1 other | 13G | 8.10%7.10M shares | New | Mar 31, 2025 | SEC |
| Feb 14, 20256:25 PM ET | Citadel Advisors LLCand 6 others | 13G/A | 4.10%3.47M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20254:15 PM ET | Schonfeld Strategic Advisors LLC | 13G/A | 6.16%5.23M shares | – | Dec 31, 2024 | SEC |
| Feb 11, 20254:00 PM ET | Soleus Capital Master Fund, L.P.and 5 others | 13G/A | 9.60%8.14M shares | – | Dec 31, 2024 | SEC |
| Feb 5, 20255:28 PM ET | BlackRock, Inc. | 13G/A | 6.80%5.74M shares | – | Dec 31, 2024 | SEC |
| Nov 14, 2024 | Vivo Capital Fund VIII, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Soleus Capital Master Fund, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Venrock Healthcare Capital Partners III, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Fairmount Funds Management LLC | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Suvretta Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 8, 2024 | BlackRock, Inc. | 13GOld format | – | – | – | SEC |
| Nov 5, 2024 | Integrated Core Strategies (US) LLC | 13G/AOld format | – | – | – | SEC |
| Oct 24, 2024 | BlackRock, Inc. | 13GOld format | – | New | – | SEC |
| Sep 16, 2024 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Jul 22, 2024 | Citadel Advisors LLC | 13GOld format | – | New | – | SEC |
| Jul 18, 2024 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Jun 7, 20241:30 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jun 7, 2024 | Soleus Capital Master Fund, L.P. | 13GOld format | – | New | – | SEC |
| Mar 7, 2024 | Point72 Asset Management, L.P. | 13GOld format | – | New | – | SEC |
| Feb 14, 2024 | Deep Track Capital, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Venrock Healthcare Capital Partners III, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Fairmount Funds Management LLC | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | LAV Biosciences Fund V, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | Suvretta Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 31, 20242:08 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Jan 25, 2024 | Integrated Core Strategies (US) LLC | 13GOld format | – | New | – | SEC |
| Oct 13, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Oct 4, 2023 | Flynn James E | 13G/AOld format | – | – | – | SEC |
| Jul 28, 2023 | Deep Track Capital, LP | 13GOld format | – | New | – | SEC |
| Jun 27, 2023 | Millennium Management LLC | 13GOld format | – | New | – | SEC |
| Mar 29, 2023 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Vivo Capital VIII, LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
17 notices from officers, directors and other affiliates planning to sell Terns Pharmaceuticals, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Jan 15, 20264:24 PM ET | Amy BurroughsDirector · Officer | 97.9K | $3.64M | Jan 15, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Nov 4, 20254:32 PM ET | Jill QuigleyDirector | 24.5K | $344.0K | Nov 4, 202510b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jan 6, 20254:29 PM ET | Mark J VignolaOfficer | 9.06K | $52.1K | Jan 6, 202510b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jan 6, 20254:29 PM ET | Jill QuigleyDirector | 8.76K | $50.4K | Jan 6, 202510b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Sep 10, 20244:21 PM ET | Seokho Bryan YoonOfficer | 10.0K | $91.2K | Sep 10, 202410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Sep 10, 20244:21 PM ET | Mark J VignolaOfficer | 10.0K | $91.2K | Sep 10, 202410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Sep 9, 20244:30 PM ET | Jill QuigleyOfficer | 8.86K | $69.2K | Sep 9, 202410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jul 15, 20247:54 PM ET | OrbiMed Asia Partners III, LPDirector · Shareholder | 131.7K | $1.23M | Jul 15, 2024 | TD Cowen | SEC |
| Jul 15, 20247:51 PM ET | OrbiMed Private Investments VII, LPDirector · Shareholder | 976.8K | $9.09M | Jul 15, 2024 | TD Cowen | SEC |
| Jul 15, 20247:48 PM ET | OrbiMed Genesis Master Fund, LPDirector · Shareholder | 152.4K | $1.42M | Jul 15, 2024 | TD Cowen | SEC |
| Jul 15, 20244:28 PM ET | Jill QuigleyDirector · Officer | 32.0K | $297.9K | Jul 15, 202410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Apr 3, 20245:13 PM ET | Vivo Capital Surplus Fund VIII, L.P.Director | 5.44K | $32.7K | Apr 3, 202410b5-1 | Cowen and Company, LLC | SEC |
| Apr 3, 20245:12 PM ET | Vivo Capital Fund VIII, L.P.Director | 39.4K | $236.5K | Apr 3, 202410b5-1 | Cowen and Company, LLC | SEC |
| Apr 3, 20245:10 PM ET | Vivo Opportunity Fund Holdings, L.P.Director | 136.3K | $817.5K | Apr 3, 202410b5-1 | Cowen and Company, LLC | SEC |
| Apr 1, 20245:13 PM ET | Vivo Capital Surplus Fund VIII, L.P.Director | 8.83K | $66.8K | Apr 1, 202410b5-1 | Cowen and Company, LLC | SEC |
| Apr 1, 20245:10 PM ET | Vivo Opportunity Fund Holdings, L.P.Director | 221.1K | $1.57M | Apr 1, 202410b5-1 | Cowen and Company, LLC | SEC |
| Apr 1, 20245:08 PM ET | Vivo Capital Fund VIII, L.P.Director | 64.0K | $454.7K | Apr 1, 202410b5-1 | Cowen and Company, LLC | SEC |